Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H17N5O |
| Molecular Weight | 307.3498 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)N1N=NN=C1CC2=CC=C(C=C2)C3=CC=CC=C3
InChI
InChIKey=GZNIYOXWFCDBBJ-UHFFFAOYSA-N
InChI=1S/C17H17N5O/c1-21(2)17(23)22-16(18-19-20-22)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
| Molecular Formula | C17H17N5O |
| Molecular Weight | 307.3498 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21764305 |
12.0 nM [IC50] | ||
Target ID: CHEMBL4191 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19583260 |
54.4 nM [IC50] |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:11:35 GMT 2025
by
admin
on
Mon Mar 31 23:11:35 GMT 2025
|
| Record UNII |
2WBU91OKM7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-LY-2183240
Created by
admin on Mon Mar 31 23:11:35 GMT 2025 , Edited by admin on Mon Mar 31 23:11:35 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
LY-2183240
Created by
admin on Mon Mar 31 23:11:35 GMT 2025 , Edited by admin on Mon Mar 31 23:11:35 GMT 2025
|
PRIMARY | LY-2183240 is a drug which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. This leads to markedly elevated anandamide levels in the brain, and LY-2183240 has been shown to produce both analgesic and anxiolytic effects in animal models. While LY-2183240 is a potent inhibitor of FAAH, it has relatively poor selectivity and also inhibits several other enzyme side targets. Consequently, it was never developed for clinical use, though it remains widely used in research, and has also been sold as a designer drug. | ||
|
874902-19-9
Created by
admin on Mon Mar 31 23:11:35 GMT 2025 , Edited by admin on Mon Mar 31 23:11:35 GMT 2025
|
PRIMARY | |||
|
DTXSID001024706
Created by
admin on Mon Mar 31 23:11:35 GMT 2025 , Edited by admin on Mon Mar 31 23:11:35 GMT 2025
|
PRIMARY | |||
|
11507802
Created by
admin on Mon Mar 31 23:11:35 GMT 2025 , Edited by admin on Mon Mar 31 23:11:35 GMT 2025
|
PRIMARY | |||
|
2WBU91OKM7
Created by
admin on Mon Mar 31 23:11:35 GMT 2025 , Edited by admin on Mon Mar 31 23:11:35 GMT 2025
|
PRIMARY | |||
|
LY-2183240
Created by
admin on Mon Mar 31 23:11:35 GMT 2025 , Edited by admin on Mon Mar 31 23:11:35 GMT 2025
|
PRIMARY | Novel and highly potent blocker of anandamide uptake (IC50 = 270 pM). Inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). Following i.p. administration in rats, increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain. |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |